TNNT2 and myositis disease: Briefly, among the six patients with biopsy‐confirmed ICI‐induced myositis, myotoxicity biomarkers (CK, cTnT) increased after the second dose of NIVO, prompting clinical evaluation and a stepwise guideline‐adapted (SITC, ESMO, ASCO) myositis treatment, including GC, intravenous immunoglobulin (IVIG), infliximab (INFLXI), and/or plasma exchange (PLEX).